Michael Yee
Stock Analyst at UBS
(3.86)
# 646
Out of 5,134 analysts
110
Total ratings
48.05%
Success rate
11.55%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLTO Galecto | Initiates: Buy | $45 | $29.91 | +50.45% | 1 | Feb 17, 2026 | |
| ABBV AbbVie | Maintains: Neutral | $240 → $230 | $228.15 | +0.81% | 2 | Feb 5, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $535 → $545 | $471.81 | +15.51% | 6 | Jan 26, 2026 | |
| GILD Gilead Sciences | Maintains: Buy | $145 → $155 | $152.60 | +1.58% | 5 | Jan 26, 2026 | |
| AMGN Amgen | Maintains: Buy | $380 → $390 | $377.65 | +3.27% | 7 | Jan 26, 2026 | |
| VTYX Ventyx Biosciences | Downgrades: Neutral | $20 → $14 | $13.96 | +0.32% | 3 | Jan 8, 2026 | |
| ACLX Arcellx | Assumes: Buy | $100 | $69.62 | +43.64% | 1 | Jan 7, 2026 | |
| IDYA IDEAYA Biosciences | Assumes: Buy | $50 | $30.73 | +62.71% | 1 | Jan 7, 2026 | |
| DNLI Denali Therapeutics | Assumes: Buy | $25 | $19.13 | +30.72% | 3 | Jan 7, 2026 | |
| IMCR Immunocore Holdings | Assumes: Buy | $24 → $55 | $32.38 | +69.86% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $3 → $12 | $6.23 | +92.62% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 → $70 | $54.79 | +27.76% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $28.08 | +78.06% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $46.72 | +28.42% | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $18 | $11.84 | +52.03% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $3.76 | +86.42% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $32.14 | +55.57% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $22.39 | +100.98% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $10 | $5.73 | +74.67% | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $39.82 | +50.68% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $24.22 | +106.44% | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $27.53 | +1.71% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.24 | +257.94% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $20.06 | +74.48% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $6.79 | +194.55% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $46 → $65 | $59.62 | +9.02% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $130 → $185 | $193.93 | -4.60% | 6 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $25 | $27.37 | -8.64% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $1,080 → $1,250 | $1,015.28 | +23.12% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $3 | $2.34 | +28.48% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $55 | $46.90 | +17.27% | 8 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $385 | $429.82 | -10.43% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $5.07 | -40.83% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $60 → $20 | $15.69 | +27.47% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $3.57 | +741.51% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $9.05 | +231.49% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $28.79 | +316.81% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $82.11 | -63.46% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $22.11 | +248.26% | 2 | Nov 8, 2018 |
Galecto
Feb 17, 2026
Initiates: Buy
Price Target: $45
Current: $29.91
Upside: +50.45%
AbbVie
Feb 5, 2026
Maintains: Neutral
Price Target: $240 → $230
Current: $228.15
Upside: +0.81%
Vertex Pharmaceuticals
Jan 26, 2026
Maintains: Buy
Price Target: $535 → $545
Current: $471.81
Upside: +15.51%
Gilead Sciences
Jan 26, 2026
Maintains: Buy
Price Target: $145 → $155
Current: $152.60
Upside: +1.58%
Amgen
Jan 26, 2026
Maintains: Buy
Price Target: $380 → $390
Current: $377.65
Upside: +3.27%
Ventyx Biosciences
Jan 8, 2026
Downgrades: Neutral
Price Target: $20 → $14
Current: $13.96
Upside: +0.32%
Arcellx
Jan 7, 2026
Assumes: Buy
Price Target: $100
Current: $69.62
Upside: +43.64%
IDEAYA Biosciences
Jan 7, 2026
Assumes: Buy
Price Target: $50
Current: $30.73
Upside: +62.71%
Denali Therapeutics
Jan 7, 2026
Assumes: Buy
Price Target: $25
Current: $19.13
Upside: +30.72%
Immunocore Holdings
Jan 7, 2026
Assumes: Buy
Price Target: $24 → $55
Current: $32.38
Upside: +69.86%
Jan 7, 2026
Assumes: Buy
Price Target: $3 → $12
Current: $6.23
Upside: +92.62%
Jan 7, 2026
Assumes: Buy
Price Target: $20 → $70
Current: $54.79
Upside: +27.76%
Jan 7, 2026
Initiates: Buy
Price Target: $50
Current: $28.08
Upside: +78.06%
Jan 7, 2026
Initiates: Buy
Price Target: $60
Current: $46.72
Upside: +28.42%
Jan 7, 2026
Initiates: Neutral
Price Target: $18
Current: $11.84
Upside: +52.03%
Jan 7, 2026
Initiates: Buy
Price Target: $7
Current: $3.76
Upside: +86.42%
Jan 7, 2026
Initiates: Buy
Price Target: $50
Current: $32.14
Upside: +55.57%
Jan 7, 2026
Initiates: Buy
Price Target: $45
Current: $22.39
Upside: +100.98%
Jan 7, 2026
Initiates: Neutral
Price Target: $10
Current: $5.73
Upside: +74.67%
Jan 7, 2026
Initiates: Buy
Price Target: $60
Current: $39.82
Upside: +50.68%
Jan 7, 2026
Initiates: Buy
Price Target: $50
Current: $24.22
Upside: +106.44%
Jan 7, 2026
Initiates: Neutral
Price Target: $28
Current: $27.53
Upside: +1.71%
Jan 7, 2026
Initiates: Buy
Price Target: $8
Current: $2.24
Upside: +257.94%
Jan 7, 2026
Initiates: Buy
Price Target: $35
Current: $20.06
Upside: +74.48%
Jan 7, 2026
Initiates: Buy
Price Target: $20
Current: $6.79
Upside: +194.55%
Jan 7, 2026
Upgrades: Buy
Price Target: $46 → $65
Current: $59.62
Upside: +9.02%
Jan 7, 2026
Assumes: Neutral
Price Target: $130 → $185
Current: $193.93
Upside: -4.60%
Jan 7, 2026
Assumes: Neutral
Price Target: $25
Current: $27.37
Upside: -8.64%
Jan 7, 2026
Assumes: Buy
Price Target: $1,080 → $1,250
Current: $1,015.28
Upside: +23.12%
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $2.34
Upside: +28.48%
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $46.90
Upside: +17.27%
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $429.82
Upside: -10.43%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $5.07
Upside: -40.83%
Oct 25, 2023
Downgrades: Hold
Price Target: $60 → $20
Current: $15.69
Upside: +27.47%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $3.57
Upside: +741.51%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $9.05
Upside: +231.49%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $28.79
Upside: +316.81%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $82.11
Upside: -63.46%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $22.11
Upside: +248.26%